Relay Therapeutics

RLAY - Relay Therapeutics • Financials

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
26
-368
-
L
L
752
L
-750
-
-386
-4
35
-390
0
0
-
-
12/2024
10
-367
-
L
L
778
L
-781
-
-343
-2
270
-345
0
0
-
-
12/2025
15
-299
-
L
L
567
L
-555
-
-298
-0
2
-298
0
0
-
-